About erythropoietin
Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein that is responsible for the production of erythrocytes in the body. In the fetal stage, this protein is produced in the liver. However, in adulthood it is produced in the kidneys. During anemic conditions, the body produces an excess of erythropoietin to maintain a normal level of red blood cells. When the endogenous production of erythropoietin is disrupted because of illness or medications, normal red blood cell levels are maintained by an injecting erythropoiesis-stimulating agents (ESAs). These agents are similar to natural erythropoietin in structure and function. They can be produced by recombinant DNA technology and are used in the treatment of anemia resulting from renal disease, cancer, HIV, injuries, or neurological conditions.
Technavio's analysts forecast the erythropoietin market in Japan to decline at a CAGR of (1.16) % over the period 2014-2019.
Covered in this report
In this report, Technavio covers the present scenario and growth prospects of the erythropoietin market in Japan for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of erythropoietin drugs and biosimilars used in the treatment of anemia due to renal disease, chemotherapy, antiretroviral therapy, wounds, or neurological conditions.
Technavio's report, Erythropoietin Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the erythropoietin market in Japan and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.
Key vendors
• Chugai Pharmaceutical
• JCR Pharmaceuticals
• Kissei Pharmaceutical
• Kyowa Hakko Kirin
Other prominent vendors
• Eisai
• Otsuka
• Taiho Pharmaceutical
• Takeda
Market driver
• Increased incidence of anemia due to illness
• For a full, detailed list, view our report
Market challenge
• High cost of therapy
• For a full, detailed list, view our report
Market trend
• Strategic alliances
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Biosimilars and biologics industry
Overview
Emerging role of biosimilars
Factors influencing biosimilars and biologics industry
Biosimilars: Business and pricing strategy
Biosimilars industry: Viewpoints of providers, payers, buyers, vendors, and regulatory bodies
PART 06: Japan: Country snapshot
Pharmaceutical industry in Japan
Biosimilars and biologics industry in Japan
Regulatory landscape
Healthcare reforms
Erythropoietin: Addressable market in Japan
PART 07: Global erythropoietin drugs market
PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 09: Market segmentation by application
End-stage renal disease
Cancer
HIV
Wounds and neural disease
PART 10: Market segmentation by product
First-generation erythropoietin formulation
Second-generation erythropoietin formulation
Biosimilars
PART 11: Market segmentation by end-user
Hospitals
Pharmacies
PART 12: Market drivers
Increased incidence of anemia
Reimbursement for erythropoietin preparations
Favorable growth opportunities
PART 13: Impact of drivers
PART 14: Market challenges
Complex manufacturing process
Complicated regulatory framework
Physician’s reluctance to prescribe biosimilars
PART 15: Impact of drivers and challenges
PART 16: Market trends
Strategic alliances
Increased R&D of innovative molecule drugs
Focus on biosimilars
PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014
PART 18: Key vendor analysis
Chugai Pharmaceutical
JCR Pharmaceuticals
Kissei Pharmaceutical
Kyowa Hakko Kirin
PART 19: Appendix
List of abbreviations
PART 20: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Definition of biosimilars by organizations
Exhibit 03: Factors influencing biosimilars and biologics industry
Exhibit 04: Patent expiries of branded biologics
Exhibit 05: Impact of biosimilar cost savings on various sectors
Exhibit 06: Factors affecting success of biosimilars
Exhibit 07: Biosimilars industry: Point-of-view
Exhibit 08: Revenue of pharmaceuticals in Japan 2013 and 2020 ($ billions)
Exhibit 09: Pharmaceutical R&D expenditure in Japan 2000-2012 ($ millions)
Exhibit 10: Japan’s percentage share in world imports of pharmaceuticals 2013
Exhibit 11: Japan’s percentage share in world exports of pharmaceutical 2013
Exhibit 12: Biosimilars approved by PMDA in Japan
Exhibit 13: Review process of biosimilars in Japan
Exhibit 14: Number of people with cancer in Japan 2010-2013
Exhibit 15: Incidence of cancers in Japan 2011
Exhibit 16: Approved erythropoietin biosimilars
Exhibit 17: Erythropoietin drugs market in Japan 2014-2019 ($ millions)
Exhibit 18: Five forces analysis
Exhibit 19: Erythropoietin drugs market in Japan by end-user 2014
Exhibit 20: Erythropoietin drugs market in Japan by product in hospitals 2014
Exhibit 21: Erythropoietin drugs market segmentation in Japan by product in retail pharmacies 2014
Exhibit 22: Number of people receiving dialysis in Japan 2008-2012
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Kyowa Hakko Kirin: YoY growth and revenue of NESP 2010-2014 ($ millions)
Exhibit 26: Kyowa Hakko Kirin: YoY growth and revenue of ESPO/NESP 2010-2012 ($ millions)
Exhibit 27: Chugai Pharmaceutical: YoY growth and revenue of Epogin 2010-2014 ($ millions)
Exhibit 28: Chugai Pharmaceutical: YoY growth and revenue of Mircera 2011-2014 ($ millions)
Exhibit 29: JCR Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection JCR 2011-2014 ($ millions)
Exhibit 30: Kissei Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection (JCR) 2011-2014 ($ millions)
Exhibit 31: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
Exhibit 32: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 33: Kissei Pharmaceutical: Business segmentation by revenue 2015
Exhibit 34: Kissei Pharmaceutical: Business segmentation by revenue 2014 and 2015 ($ millions)
Exhibit 35: Kissei Pharmaceutical: Geographical segmentation by revenue 2015
Exhibit 36: Kyowa Hakko Kirin: Business segmentation by revenue 2014
Exhibit 37: Kyowa Hakko Kirin: Business segmentation by revenue 2013 and 2014
Exhibit 38: Kyowa Hakko Kirin: Geographical segmentation by revenue 2014
